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The complement system is a major pillar of the humoral innate immune system. As a 
first line of defense against pathogens, it mediates early inflammatory response and links 
different branches of humoral and cellular immunity. Disorders affecting the exocrine 
pancreas, such as acute pancreatitis, potentially lead to a life-threatening systemic inflam-
matory response with aberrant activation of complement and coagulation cascades. 
Pancreatic proteases can activate key effectors of the complement system, which in turn 
drive local and systemic inflammation. Beyond that, the extent of pancreas–complement 
interaction covers complex pro- and anti-inflammatory mechanisms, which to this day 
remain to be fully elucidated. This review provides a comprehensive overview of the 
pathophysiological role of complement in diseases of the exocrine pancreas, based on 
existing experimental and clinical data. Participation of complement in acute and chronic 
pancreatitis is addressed, as well as its role in tumor immunology. Therapeutic strategies 
targeting complement in these diseases have long been proposed but have not yet 
arrived in the clinical setting.
Keywords: pancreas, complement, pancreatitis, acinar cells, multiple organ failure, pancreatic ductal 
adenocarcinomas
iNTRODUCTiON
The pancreas is a central and highly interconnected organ, anatomically as well as metabolically. 
In local and systemic inflammation, the pancreas is critically involved both as target and effec-
tor. Moreover, the pancreas seems to have a so far underappreciated major impact in triggering, 
development, and progression of multiple organ dysfunction syndrome (MODS) (1). Clinically 
and experimentally, manifold interactions of the pancreas with the innate and adaptive immune 
system have been described (2). On a cellular level, leukocytes seem to be significantly affected 
by pancreatic proteases and mediators that in turn promote local pancreatic (3–5) and systemic 
inflammation (2). In critically ill patients, e.g., after tissue trauma–hemorrhage, during systemic 
inflammation, infection, or sepsis, both danger- and pathogen-associated molecular patterns can 
induce an excessive activation of the complement system (6). The generated complement activation 
products are potent drivers of local and systemic inflammation and major contributors to MODS 
(7, 8). However, the pathophysiological interactions of the complement cascade with the pancreas 
[e.g., during acute pancreatitis (AP)] are rather complex, are partially controversial, and might have 
been underestimated so far (9). It is even more surprising that the physiological role of complement 
concerning the exocrine function of the pancreas has barely been investigated.
The aim of this comprehensive review is to provide an up-to-date insight into the interactions of 
complement with the exocrine pancreas based on experimental and clinical data. The review will 
neither cover the various functions of complement in regard to the endocrine pancreas (10–14) nor 
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address the potential harmful role of complement in the context 
of pancreas whole organ and islet transplantation (15–17). The 
focus of the present review is rather set on various important pan-
creatic diseases in the light of complement action and regulation.
COMPLeMeNT AS A MAiN PiLLAR OF 
iNNATe iMMUNiTY
The cellular and humoral defense systems of innate immunity 
are crucially involved in inducing and mounting local inflamma-
tory processes, systemic inflammation, and remote organ injury. 
Main pathophysiological drivers of the inflammatory response 
are the complement and coagulation cascasdes, which are highly 
interactive and can also be considered parts of a global serine 
protease system (18). It is well established that severe pancreatic 
tissue damage and pancreatitis is associated with activation 
of the coagulation system, often resulting in development of 
coagulopathy. In contrast, activation of the complement system 
and development of complementopathy in the setting of severe 
pancreatic diseases has not been conclusively investigated so far.
The complement system as a key immune surveillance system 
(19) consists of more than 30 complement components, which 
can be activated by different pathways. Complement activation 
via classical, alternative, and lectin pathways has been described 
in great detail before. The main drivers of these pathways are 
outlined in Figure 1.
It is noteworthy that various complement factors can be 
activated in a non-canonical manner by an “extrinsic protease 
pathway” (19), consisting of serine proteases of the coagulation 
and fibrinolytic system (e.g., thrombin, plasmin, and factor VII-
activating serine protease) (20, 21). Furthermore, other proteases 
such as granzyme B (22) and trypsin (23) are capable of cleav-
ing and activating central complement components, leading to 
generation of the anaphylatoxins C3a and C5a, which in turn can 
induce all classical signs of inflammation.
To prevent excessive activation, hyper-inflammation, and 
self-attack, the complement cascade is tightly regulated and con-
trolled by complement regulatory proteins (CRegs). Main inhibi-
tors within the fluid phase system are the C1 inhibitor (C1INH), 
C4-binding protein (C4bp), complement factor H, and comple-
ment factor I. On cellular surfaces there are also some potent 
surface-bound CRegs, e.g., complement receptor 1 (CR1, CD35), 
membrane cofactor protein (MCP, CD46), decay accelerating 
factor (DAF, CD55), and membrane inhibitor of reactive lysis 
(CD59). The balance between complement activation products 
and counteracting CRegs may be disturbed in many diseases, 
especially by the uncontrolled release of other potent proteases, 
e.g., during massive activation of the coagulation system or dur-
ing inflammatory processes of the pancreas.
eXOCRiNe PANCReAS AND 
COMPLeMeNT AS CeNTRAL PLAYeRS iN 
MULTiPLe ORGAN DYSFUNCTiON
It has been suggested that digestive enzymes (prematurely) 
released from the exocrine pancreas can enter the circulation 
via dysfunctional organ barriers. In the systemic circulation, 
these pancreas-derived proteases may cleave off cellular surface 
molecules and receptors and activate other proteases (24, 25), 
such as coagulation, fibrinolytic, and complement factors. The 
resulting “autodigestion” and dysregulation of important innate 
immune cascades reflect main pathophysiological features of 
MODS. Activated trypsin has been suggested to be ultimately 
responsible for MODS development, causing enhanced global 
organ permeability, blood exudate leakage, and coagulation 
dysfunction (26).
Other mechanisms by which local pancreatic damage affects 
MODS have been proposed. In experimental pancreatitis, reduc-
tion of phosphorylation processes, impairment of the respiratory 
chain, and resulting severe mitochondrial dysfunction were 
found to facilitate further pancreatic damage. Beyond these 
local effects, mitochondrial function in the lungs and kidneys 
was also reduced early after induction of pancreatitis (27). A 
time-dependent onset of MODS (lung, kidney, heart, and liver) 
induced by experimental pancreatitis with associated acinar cell 
necrosis and systemic inflammatory response has been reported 
to involve neutrophil influx and extracellular regulated kinase 
(ERK) activation (28). Immune cell infiltration of lung tissue 
during experimental pancreatitis has been shown to be accompa-
nied by enhanced expression of endothelial adhesion molecules, 
such as intercellular adhesion molecule-1 (ICAM-1) (29). 
Furthermore, when AP is complicated by infection, the excessive 
cytokine release and inflammatory response by macrophages 
further prime neutrophils for a “second attack” on remote organs 
(30) (Figure 2).
It is remarkable that most of the proposed mechanisms of 
pancreas-induced MODS have also been proposed in the context 
of systemic complement activation. It is of course questionable if 
complement activation per se is causative, contributive, or merely 
associated with MODS development. However, it is well estab-
lished that the complement activation product C5a enhances 
ICAM-1 expression, effectively recruits and primes neutrophils, 
potentiates the cytokine release, activates multiple signaling 
pathways such as ERK, modulates the vascular tonus and micro-
perfusion, and interacts with the coagulation system—only to 
mention some C5a effects (31, 32). Strikingly, in vivo blockade 
of C5a–C5aR interaction in sepsis-induced rodent MODS coun-
teracted neutrophil dysfunction and protected cellular function 
on a multiple organ level, resulting in a significantly improved 
survival of MODS (7, 33, 34). Recently, a novel C5a-neutralizing 
mirror-image (l-)aptamer prevented organ failure and peritoneal 
barrier dysfunction in experimental sepsis (35), indicating C5a 
as a central player in MODS development. However, based on 
current literature, pancreas as a remote target of other severe 
organ dysfunction (such as ischemia/reperfusion injury of the 
kidney) has never been addressed in the context of comple-
ment activation. On the other hand, there is clear evidence that 
pancreatitis is associated with systemic complement activation 
(36), which per  se may contribute to MODS development. In 
addition, the complement–coagulation cross talk (18, 20) cer-
tainly is crucially involved in progression of MODS and multiple 
organ failure (8, 34), with a potential role for the pancreas as a 
local and remote target. Concerning the spatial and temporal 
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FiGURe 2 | exocrine pancreas and complement as central players in 
multiple organ dysfunction. In the context of acute pancreatitis, cross talk 
between complement, coagulation, and immune cells, such as neutrophil 
granulocytes and monocytes, drives multiple organ dysfunction. Systemic 
inflammatory response in turn mediates local organ damage and dysfunction. 
Abbreviations: ALF, acute liver failure; ARDS, acute respiratory distress 
syndrome; AKI, acute kidney injury.
Complement activation. The classical pathway recognizes immunoglobulins (IgM/IgG) and pentraxins (such as C-reactive protein) and forms and activates a C1 
complex, leading to the cleavage of C4 and C2. The cleavage products C4b and C2a form the C3 convertase C4b2a of the classical pathway, which in turn cleaves 
the central complement component C3 into the anaphylatoxin C3a and opsonin C3b. The C3 convertase can also be formed and activated by the lectin pathway, in 
which mannose-binding lectin (MBL) and ficolins recognize pathogenic patterns, leading to the activation of MBL-associated serine proteases MASP-1 and 
MASP-2. The alternative pathway, triggered by various danger- and pathogen-associated molecular patterns (DAMPS and PAMPS, respectively) on necrotic, 
apoptotic, and foreign surfaces, involves hydrolisation of C3 and cleavage by other complement factors. Binding of factor B (FB) to C3(H2O) results in the formation 
of an alternative fluid phase C3 convertase. C3 is cleaved, and C3b binds FB to form the surface-bound main C3 convertase of the alternative pathway, which is 
stabilized by properdin (P) and can in turn induce all functions of complement (C3bBbP). The alternative pathway also constitutes an amplification loop for the 
complement cascade, with C3b as a feedback effector. Besides enhancing the complement response, as an opsonin, C3b is also essential for the clearance of 
pathogens and tissue debris. Downstream of the converging activation pathways, the C3 convertases of both classical and alternative pathways bind C3b and form 
the respective C5 convertases. Those cleave C5, producing the potent anaphylatoxin C5a and C5b. The latter, together with several other complement factors (C6, 
C7, C8, and C9), forms the terminal complement complex (TCC), also known as membrane attack complex. This C5b–9 complex induces both pro- and 
anti-inflammatory cell signaling pathways and is also capable to form a lytic pore. Cleavage and activation of central complement components is also possible by 
proteases typically not associated with the complement system, such as trypsin—effectively constituting a fourth, non-canonical extrinsic protease pathway of 
complement activation (targets shown exemplarily). Important regulators of the complement cascade (CRegs) are C1 inhibitor (C1INH), factor H (FH), and membrane 
inhibitor of reactive lysis (CD59). Several CRegs control the formation, activity, and degradation of C3 convertase, which can be classical, alternative, or both. CD35, 
C4bp, and FH, shown here acting on the convertases themselves, can also function as cofactors for FI-mediated cleavage of upstream components C3b or C4b. 
CD35 = complement receptor 1 (CR1); CD46 = membrane cofactor protein (MCP); CD55 = decay accelerating factor (DAF); FI, factor I; C4bp, C4-binding protein.
FiGURe 1 | Continued
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pattern of MODS development in the context of inflammatory 
pancreatic diseases, it is noteworthy that there is clinically and 
experimentally no characteristic pattern of organ failure onset. 
The order of affected organs rather seems to be dependent on 
the used experimental model and on the nature of the initiating 
pathogenic trigger (28, 37).
COMPLeMeNT iN THe 
PATHOPHYSiOLOGY OF AP
Acute pancreatitis is a disease with extensive systemic effects, not 
only limited to its organ of origin. Intrapancreatic trypsinogen 
activation, mediated by cathepsin B, leads to autodigestion and 
promotes local organ damage (38). The ensuing destruction of 
exocrine parenchyma leads to a systemic inflammatory response 
with massive cytokine release and activation of the coagulation 
and kinin cascades. These effects can, in severe cases, lead to acute 
respiratory distress syndrome (ARDS), shock, and MODS. The 
pathomechanisms of complement involvement in local organ 
damage and systemic inflammatory response are outlined in 
Figures 3 and 4, respectively.
The complement system has long been implicated as an effector 
of local and distant inflammation in the pathogenesis and disease 
progression of AP. As early as 1975, it has been hypothesized that 
complement activation could be a factor initiating acinar cell 
damage in early necrotizing pancreatitis, which in turn leads to 
autodigestion by pancreatic enzymes (39–41). Decreased levels 
of serum complement components C3 and C4 during AP hinted 
at complement consumption and a potential role in driving local 
and systemic inflammation (42). While complement consump-
tion in AP had been described by several authors at the time, 
one early study looking for C3 deposits in the pancreas during 
simultaneously falling C3 serum levels found no such stainable 
complement deposits in a murine model of dl-ethionine-induced 
AP (43, 44).
On the other hand, cleavage of C3 by the pancreatic protease 
trypsin with subsequent complement activation, a process only 
partly ameliorated by anti-proteolytic mechanisms in the pro-
cess of excess trypsin release and activation, provides evidence 
of strong pancreas–complement interaction (45) (Figure  3). 
Complement activation seems to happen by both classical and 
alternative complement pathways, and the extent of changes in 
complement serum levels shows a correlation with the clinical 
severity of disease (36, 46, 47). Only severe necrotizing pan-
creatitis, but not mild edematous AP, in rats was accompanied 
FiGURe 3 | Role of complement in the pathophysiology of acute and chronic pancreatitis. The figure showcases some of the known complement–
pancreas interactions as described in Sections “Complement in the Pathophysiology of Acute Pancreatitis” and “Implication of Complement in Chronic Pancreatitis 
and Autoimmune Pancreatitis.” Complement activation can induce acinar cell damage in early pancreatitis, which leads to autodigestion by pancreatic enzymes. 
Pancreatic proteases then in turn cleave and activate complement factors within the pancreas. Abbreviations: C3–C5, complement factor 3–5; C5aR, C5a receptor; 
FB, factor B; FH, factor H; PSC, pancreatic stellate cells; αSMA, alpha smooth muscle actin.
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by early complement activation with increased levels of C3a (48). 
Similar results linking decreasing complement hemolytic activ-
ity (CH50), acinar C3 deposits, and histological tissue damage 
could be found in a rodent model of AP (49). It is noteworthy 
that complement consumption in early AP can be accompanied 
by persistently lowered serum complement levels several weeks 
after the onset of symptoms (50).
In the clinical setting, C3a and sC5b–9 are elevated in 
the serum of patients with early AP and also show an excel-
lent correlation with severity of disease, suggesting them as 
potential biomarkers for severe AP with high specificity and 
sensitivity (51). Patients who developed pancreatic pseudocysts 
as a result of AP showed changes in plasma complement activ-
ity and protease inhibitors similar to those seen in moderate 
to severe AP without pseudocysts (52). Pseudocyst fluid 
itself, as well as ascites of patients with AP, has been shown to 
contain high levels of C5a and terminal complement complex 
(TCC) (47).
Vice versa, in the absence of C5, C5-deficient mice develop 
significantly less pancreatic edema in the course of AP (53).
One recent study quantifying mannose-binding lectin (MBL) 
pathway effectors in AP patient sera found no significant cor-
relation between levels of MBL, MBL-associated serine protease 
2, and severity or mortality of disease. These findings suggest 
that the MBL pathway of complement activation only plays a 
minor role in AP pathogenesis (54). Fittingly, pancreatic MBL, 
isolated from pancreatic juice and identified as pancreatic elastase 
III, could not be shown to induce complement-mediated lysis, 
contrasting starkly with other known MBL isoforms (55).
The role of protease–anti-protease imbalance in this context 
has been extensively discussed, with contrasting results by dif-
ferent researchers, hinting at a more prominent role in local 
FiGURe 4 | Complement as a mediator of systemic inflammatory response during pancreatitis. Local tissue destruction and complement activation 
caused by severe acute pancreatitis lead to a systemic inflammatory response, which can culminate in ARDS, shock, and multiple organ dysfunction. For details, 
see text. Abbreviations: ARDS, acute respiratory distress syndrome; C3–C5, complement factor 3–5; CTX, chemotaxis; IFN, interferon; IL, interleukin; sCR1, soluble 
complement receptor type 1; TGF, transforming growth factor; TNFα, tumor necrosis factor α; TCC, terminal complement complex.
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intraperitoneal trypsin activity as opposed to systemic (serum) 
activity. A low level of the anti-protease alpha-2-macroglobulin is 
an universally acknowledged predisposing factor for high trypsin 
activity (46, 56–59). Regarding protease–complement interac-
tions, trypsin-induced C3 cleavage could be inhibited in vitro by 
high levels of pancreatic secretory trypsin inhibitor (60).
In addition to excessive complement cleavage and activation, 
loosening of physiologic inhibitory mechanisms controlling com-
plement activity also plays a role in the pathophysiology of AP. 
The complement activation regulators CD46, CD55, and CD59, 
normally expressed on pancreatic acinar cells, are downregulated 
in sodium taurocholate-induced severe AP, and decreased expres-
sion is correlated with more severe necrosis. Downregulation of 
CD55 and CD59 could be alleviated by IL-4, with a positive effect 
on disease severity (61).
Interactions between humoral innate immunity and cellular 
immunity are decisive in the inflammatory response associated 
with AP. Different immune cells have been identified as impor-
tant effectors in AP, especially macrophages and neutrophils 
(62). While data are scarce on macrophage/monocyte involve-
ment in pancreatic complement modulation, the activation of 
neutrophil granulocytes by the complement system has been a 
focus of research. Especially, C5a is known to be a strong chem-
oattractant for neutrophil recruitment to damaged and inflamed 
tissue and can induce phagocytosis, release of cytokines, and 
oxidative burst with release of reactive oxygen species (63). 
Thus, C5a may represent a main driver for neutrophil migra-
tion to pancreatic tissue, as well as to lung tissue in AP-related 
ARDS (64) (Figure 4). Neutrophils incubated with serum from 
rats suffering from necrotizing AP showed increased expression 
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of the adhesion molecule membrane attack complex (MAC)-1 
(CD11b/18, complement receptor 3). In addition, injection of 
AP serum into lung tissue led to local neutrophil sequestration. 
Both effects were averted by complement inhibition with soluble 
complement receptor type 1 (sCR1) (65). In another rat model 
of acute severe/necrotizing and mild/edematous AP, inhibition 
of complement activation by administration of sCR1 decreased 
leukocyte–complement interaction and local and remote lung 
damage (48). Severe necrotizing AP seems to lead to a reduced 
expression of opsonin receptors, including complement recep-
tor 3 on local peritoneal neutrophils, and enhanced expression 
on circulatory neutrophils. Nearly opposite changes were found 
in mild pancreatitis (66, 67). A 2001 study by Kyriakides et al. 
assessed the effects of total neutrophil and/or complement 
depletion in experimental AP. While local pancreas damage 
was not modified by either of those, neutropenia, but not 
complement depletion, showed a beneficial effect on remote 
organ injury and overall survival (68). This suggests that besides 
complement-mediated neutrophil activation, other mediators 
significantly contribute to the activation of cellular immune 
response during AP.
Contrasting anti-inflammatory effects of complement 
components have been reported in a 2001 study conducted by 
Bhatia et al. (69). In genetically modified mice lacking either C5 
or C5a receptor, cerulein-induced pancreatitis was characterized 
by a distinctly more severe clinical progression as compared to 
wild-type mice, with aggravated local pancreas as well as remote 
lung injury. These findings hint at an anti-inflammatory role of 
C5a in AP. It should be noted that, when excessively generated, 
C5a eventually results in a functional paralysis of the neutrophil 
response (70) and thereby might represent a mechanism for 
inhibiting neutrophil-mediated pancreatic damage.
In conclusion, the role of the complement system in AP 
seems to be highly complex and is not yet fully understood. 
Opposing interactions concerning local and systemic inflamma-
tory response have been proposed. Likely, both pro- and anti-
inflammatory effects are conveyed by different key components 
within the complement cascade. On another note, the widespread 
usage of a number of different animal models, which vary consid-
erably in their modes and mechanisms of AP induction, may have 
contributed to conflicting results.
iMPLiCATiON OF COMPLeMeNT iN 
CHRONiC PANCReATiTiS (CP) AND 
AUTOiMMUNe PANCReATiTiS (AiP)
In comparison to AP, not much research has been done on the 
role of complement in chronic or recurring pancreatitis as well as 
in AIP. The latter is sometimes associated with decreased serum 
complement levels, accompanied by high levels of circulating 
immune complexes during the active phase of disease, an effect 
hinting at complement activation via the classic pathway (71, 72). 
These immune complexes lead to the destruction of acinar cells 
and small- to medium-sized pancreatic ducts, as suggested by 
fluorescence staining for basal membrane deposits of C3c and 
immunoglobulins (73).
Concerning complement activity in CP, a recent study by 
Sendler et al. showcases the involvement of complement C5 in 
the development of fibrosis during CP. In C5-deficient mice, CP 
was induced by pancreatic duct ligation and cerulein injection 
or recurring cerulein injections alone. Mice lacking C5, as well 
as wild-type mice subjected to treatment with C5a-receptor 
antagonists, showed significantly reduced pancreatic fibrosis in 
later stages of disease. This seems to be a consequence of recruit-
ment and activation of pancreatic stellate cells by C5a, shown 
in  vitro and in  vivo, leading to the production of extracellular 
matrix proteins (e.g., collagen type I, fibronectin, and αSMA) 
and fibrosis (74) (Figure 3). Interestingly, no major differences in 
disease severity and organ damage were noted during early stages 
of pancreatitis, which contradict the common understanding of 
complement involvement in AP.
POTeNTiAL ROLe OF COMPLeMeNT  
iN PANCReATiC TUMORiGeNeSiS
Pancreatic cancer is among the most lethal common malignan-
cies, as it is usually diagnosed at an advanced stage when curative 
therapies are no longer available. Pancreatic ductal adenocarcino-
mas (PDAC) constitute the overwhelming majority of pancreatic 
neoplasms. PDAC is characterized by extensive stromal desmo-
plasia, which promotes a hypovascular tumor microenvironment 
and immune evasion.
The inhibitory complement regulatory proteins CD46, CD55, 
and CD59 are known to be overexpressed in PDAC cell lines 
in a manner similar to other tumor entities (75, 76). This may 
contribute to immune evasion and impedes the potential of 
new immunotherapeutic strategies with monoclonal antibod-
ies, which typically rely on complement-mediated cytotoxicity 
(77). Elevated serum levels of the inhibitory anti-proteases 
alpha-2-macroglobulin and C1INH constitute an additional 
mechanism of complement resistance in pancreatic cancer (78). 
Proteomic analysis of the cell line secretome confirmed inhibi-
tion of the complement system as a major functional alteration in 
PDAC (79). Furthermore, it has been shown that under inflam-
matory conditions, complement C3 secretion in PDAC cell lines 
was inhibited by TGF-β, a cytokine strongly involved in PDAC 
progression and tissue desmoplasia (80, 81).
Inhibition of the MBL pathway of complement activation 
has been described for a subgroup of PDAC patients. In a phase 
II clinical trial, treatment with ω-3-rich fatty acids in addition 
to chemotherapy restored MBL activity and improved patient 
survival (82).
The search for novel potential biomarkers for pancreatic 
cancer has led to several studies involving proteomics analysis of 
PDAC patient sera. Several authors describe elevated serum levels 
of complement components, such as C3, C3c, C5a, and C5b–9/
MAC (83–86), as well as soluble iC3b, a complement product 
generated by the interaction with the abundantly expressed 
CRegs (87). Complement factor B has been proposed as a prom-
ising new serological biomarker for PDAC, supplementing CA 
19-9 (88). However, biomarker performance, including C5, is 
severely impeded by obstructive jaundice, a pathology common 
in pancreatic cancer (89).
8Bettac et al. Complement in Pancreatic Disease
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It is also notable that C4b1 expression in tumor tissue correlates 
with TNM staging (TNM Classification of Malignant Tumours, 
in which extent of disease is assessed by tumor size and infiltra-
tion, lymph node, and distant metastasis), with locally advanced 
and metastatic tumors showing higher expression levels (90).
To give one example for the relevance of complement in the 
setting of non-adenocarcinoma tumors of the pancreas, one 
recent study found a pro-tumorigenic role for C5 in neuroendo-
crine pancreatic tumors, with C5-deficient mice showing smaller 
primary tumors and fewer metastases. Likewise, in human NET 
samples, advanced tumors showed higher C5 expression than 
tumors with lower TNM staging (91).
Taken together, these findings suggest a balance of pro-
inflammatory and anti-inflammatory complement modulation in 
PDAC. Pancreatic cancer is known to induce a pro-inflammatory 
microenvironment, promoting growth and metastasis, which 
involves the classical complement pathway. On the other hand, 
immune evasion of cancer cells themselves could be mediated 
by inhibition of MBL and upregulation of membrane-bound 
complement regulators.
THeRAPeUTiC COMPLeMeNT 
STRATeGieS iN PANCReATiC DiSeASeS
Considering the aforementioned widespread implications of 
complement in the pathophysiology of a variety of different 
pathologies of the pancreas, only limited data exist on the possible 
therapeutic possibilities of targeted complement modulation in 
these diseases.
Combined treatment with C1 esterase inhibitor, an inhibi-
tor of the classical complement pathway, and antithrombin III 
improved survival in a rodent model of severe AP. In contrast, the 
same treatment showed no significant benefit in mild edematous 
AP (92). Likewise, treatment with C1 esterase inhibitor improved 
the clinical outcome of severe AP after allogeneic hematopoietic 
stem cell transplantation in a case study of two pediatric patients. 
This therapeutic effect was mainly attributed to reduction of 
capillary leakage and subsequent cardiovascular stabilization 
(93). In a small-scale study of patients undergoing endoscopic 
papillosphincterotomy, C1INH prevented hyperamylasemia, a 
possible precursor of post-ERCP pancreatitis (94).
One other study found no beneficial effect of complement 
inhibition by sCR1 on cerulein-induced AP (95), while a later 
study with comparable methodology found an ameliorating effect 
on neutrophil accumulation in lung tissue, indicating therapeutic 
options for distant organ damage (96).
The positive effect of C5a-receptor blockage by the small 
molecule inhibitor W-54011 on fibrosis and disease progression 
in a rodent model of CP suggests therapeutical applicability in the 
chronic setting (74). One earlier study had seen similar results 
for the serine protease inhibitor camostat (97). Owning to the 
more generalized nature of inhibition, broad band serine protease 
inhibitors, although effective in complement inhibition, could 
be expected to carry more unwanted side effects than targeted 
complement inhibition. A recent meta-analysis of 17 clinical 
trials conducted over the last five decades could find no evidence 
for a beneficial effect of i.v. treatment with protease inhibitors on 
overall mortality in AP (98). Overall, no therapeutic strategies 
targeting complement in pancreatic diseases have been clini-
cally established so far although complement modulation seems 
promising for the treatment of acute and CP.
FUTURe AveNUeS FOR COMPLeMeNT 
ReSeARCH iN PANCReATiC DiSeASeS
The data available clearly point to an important role of comple-
ment in induction and progression of acute and chronic inflam-
matory pancreatic diseases. However, it needs to be clarified 
whether the apparent Janus-faced nature of C5a in the develop-
ment of pancreatitis is merely a question of concurrence with 
anti-inflammatory features during acute and pro-inflammatory 
features during chronic inflammation.
It is noteworthy that plasma anaphylatoxin levels correlate 
with the severity of pancreatitis (36, 46, 47). Therefore, it 
would be of utmost interest to determine whether this is only a 
reflection of systemic inflammation, or if the complement acti-
vation products are causative to induction and progression of 
pancreatitis and resulting complications. It seems that the role 
of local, uncanonical activation of complement by prematurely 
activated pancreatic proteases in the progression of pancreatitis 
has been rather underestimated. Thus, it is of importance to 
define which complement components can be locally produced 
by acinar cells and ductal epithelium and investigate the con-
ditions of local complement cleavage and activation. In this 
regard, it is also surprising that no reports exist on the different 
anaphylatoxin receptor status (e.g., C3aR, C5aR1, and C5aR2) 
of pancreatic acinar cells. If detected, it would be of interest to 
characterize cellular signaling and functional consequences of 
these receptors.
Investigations of the role of complement in chronic inflam-
matory microenvironmental changes and cancer development 
are, if at all, in statu nascendi, but the subject certainly offers 
ample room for promising future research. In the light of recent 
findings linking C5 to fibrosis in CP (74), complement involve-
ment in PDAC desmoplasmic stromal response could prove to 
be an interesting research topic. Furthermore, it has been shown 
in non-pancreatic tissues that complement proteins contribute 
to immune surveillance of malignant tumors (99). C5a in the 
tumor microenvironment notably enhanced tumor growth by 
inhibiting CD8+ T cell-mediated antitumor effects (100). On the 
other hand, iC3b opsonizes tumor surfaces and thereby supports 
tumor cell cytotoxicity, which is aided by a functional TCC (101). 
These contrasting findings highlight the need for further research 
into the role of complement components in pancreatic tumor 
development.
AUTHOR CONTRiBUTiONS
LB contributed to the conception, drafting, and writing of the 
manuscript, design and preparation of the figures, final approval, 
and agreement to any part of the work. SD contributed to the 
conception of the manuscript, critical revision of the work, design 
and preparation of the figures, final approval, and agreement to 
any part of the work. TS contributed to the conception of the 
9Bettac et al. Complement in Pancreatic Disease
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 15
ReFeReNCeS
1. Gasparovic V, Dakovic K, Gornik I, Radonic R. Severe acute pancreatitis as a 
part of multiple dysfunction syndrome. Coll Antropol (2014) 38:125–8. 
2. Shamoon M, Deng Y, Chen YQ, Bhatia M, Sun J. Therapeutic implications of 
innate immune system in acute pancreatitis. Expert Opin Ther Targets (2016) 
20:73–87. doi:10.1517/14728222.2015.1077227 
3. Chen G, Xu F, Li J, Lu S. Depletion of neutrophils protects against l- 
arginine-induced acute pancreatitis in mice. Cell Physiol Biochem (2015) 
35:2111–20. doi:10.1159/000374017 
4. Merza M, Hartman H, Rahman M, Hwaiz R, Zhang E, Renstrom E, et al. 
Neutrophil extracellular traps induce trypsin activation, inflammation, and 
tissue damage in mice with severe acute pancreatitis. Gastroenterology (2015) 
149:1920–31. doi:10.1053/j.gastro.2015.08.026 
5. Schmidt AI, Seifert GJ, Lauch R, Wolff-Vorbeck G, Chikhladze S, Hopt UT, 
et al. Organ-specific monocyte activation in necrotizing pancreatitis in mice. 
J Surg Res (2015) 197:374–81. doi:10.1016/j.jss.2015.03.075 
6. Ehrnthaller C, Ignatius A, Gebhard F, Huber-Lang M. New insights of an old 
defense system: structure, function, and clinical relevance of the complement 
system. Mol Med (2011) 17:317–29. doi:10.2119/molmed.2010.00149 
7. Huber-Lang M, Sarma VJ, Lu KT, McGuire SR, Padgaonkar VA, Guo RF, 
et  al. Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 
166:1193–9. doi:10.4049/jimmunol.166.2.1193 
8. Rittirsch D, Redl H, Huber-Lang M. Role of complement in multiorgan 
failure. Clin Dev Immunol (2012) 2012:962927. doi:10.1155/2012/962927 
9. Mansfield C. Pathophysiology of acute pancreatitis: potential application 
from experimental models and human medicine to dogs. J Vet Intern Med 
(2012) 26:875–87. doi:10.1111/j.1939-1676.2012.00949.x 
10. Luan NM, Iwata H. Xenotransplantation of islets enclosed in agarose 
microcapsule carrying soluble complement receptor 1. Biomaterials (2012) 
33:8075–81. doi:10.1016/j.biomaterials.2012.07.048 
11. Phieler J, Garcia-Martin R, Lambris JD, Chavakis T. The role of the comple-
ment system in metabolic organs and metabolic diseases. Semin Immunol 
(2013) 25:47–53. doi:10.1016/j.smim.2013.04.003 
12. Tjernberg J, Ekdahl KN, Lambris JD, Korsgren O, Nilsson B. Acute anti-
body-mediated complement activation mediates lysis of pancreatic islets cells 
and may cause tissue loss in clinical islet transplantation. Transplantation 
(2008) 85:1193–9. doi:10.1097/TP.0b013e31816b22f3 
13. Tokodai K, Goto M, Inagaki A, Nakanishi W, Ogawa N, Satoh K, et  al. 
Attenuation of cross-talk between the complement and coagulation cascades 
by C5a blockade improves early outcomes after intraportal islet transplan-
tation. Transplantation (2010) 90:1358–65. doi:10.1097/TP.0b013e318 
1ffb9f5 
14. Tokodai K, Goto M, Inagaki A, Imura T, Nakanishi W, Satomi S. Expression 
of receptors for anaphylatoxins C3a and C5a on rat islet preparations. 
Transplant Proc (2011) 43:3179–80. doi:10.1016/j.transproceed.2011. 
10.006 
15. de Kort H, Munivenkatappa RB, Berger SP, Eikmans M, van der Wal A, de 
Koning EJ, et al. Pancreas allograft biopsies with positive c4d staining and 
anti-donor antibodies related to worse outcome for patients. Am J Transplant 
(2010) 10:1660–7. doi:10.1111/j.1600-6143.2010.03079.x 
16. Munivenkatappa RB, Philosophe B, Papadimitriou JC, Drachenberg CB. 
Interacinar c4d staining in pancreas allografts. Transplantation (2009) 
88:145–6. doi:10.1097/TP.0b013e3181aae779 
17. Suermann A, Vonend O, Schenker P, Viebahn R, Rump LC, Weiner SM. 
Plasma complement 3d levels in the early phase after pancreas transplanta-
tion. Ann Transplant (2009) 14:29–35. 
18. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, 
et al. Generation of C5a in the absence of C3: a new complement activation 
pathway. Nat Med (2006) 12:682–7. doi:10.1038/nm1419 
19. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system 
for immune surveillance and homeostasis. Nat Immunol (2010) 11:785–97. 
doi:10.1038/ni.1923 
20. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, Acker B, et al. Molecular 
intercommunication between the complement and coagulation systems. 
J Immunol (2010) 185:5628–36. doi:10.4049/jimmunol.0903678 
21. Kanse SM, Gallenmueller A, Zeerleder S, Stephan F, Rannou O, Denk S, et al. 
Factor VII-activating protease is activated in multiple trauma patients and 
generates anaphylatoxin C5a. J Immunol (2012) 188:2858–65. doi:10.4049/
jimmunol.1103029 
22. Perl M, Denk S, Kalbitz M, Huber-Lang M. Granzyme B: a new crossroad 
of complement and apoptosis. Adv Exp Med Biol (2012) 946:135–46. 
doi:10.1007/978-1-4614-0106-3_8 
23. Minta JO, Man DP. Cleavage of human C5 by trypsin: characterization of the 
digestion products by gel electrophoresis. J Immunol (1977) 119:1597–602. 
24. Altshuler AE, Kistler EB, Schmid-Schonbein GW. Autodigestion: proteolytic 
degradation and multiple organ failure in shock. Shock (2016) 45:483–9. 
doi:10.1097/SHK.0000000000000544 
25. Schmid-Schonbein GW, Chang M. The autodigestion hypothesis for shock 
and multi-organ failure. Ann Biomed Eng (2014) 42:405–14. doi:10.1007/
s10439-013-0891-6 
26. Sha H, Ma Q, Jha RK. Trypsin is the culprit of multiple organ injury with 
severe acute pancreatitis. Med Hypotheses (2009) 72:180–2. doi:10.1016/ 
j.mehy.2008.09.007 
27. Trumbeckaite S, Kuliaviene I, Deduchovas O, Kincius M, Baniene R, 
Virketyte S, et  al. Experimental acute pancreatitis induces mitochondrial 
dysfunction in rat pancreas, kidney and lungs but not in liver. Pancreatology 
(2013) 13:216–24. doi:10.1016/j.pan.2013.04.003 
28. Yuan Z, Meyerholz DK, Twait EC, Kempuraj D, Williard DE, Samuel I. 
Systemic inflammation with multiorgan dysfunction is the cause of death 
in murine ligation-induced acute pancreatitis. J Gastrointest Surg (2011) 
15:1670–8. doi:10.1007/s11605-011-1643-2 
29. Masamune A, Shimosegawa T, Kimura K, Fujita M, Sato A, Koizumi M, et al. 
Specific induction of adhesion molecules in human vascular endothelial cells 
by rat experimental pancreatitis-associated ascitic fluids. Pancreas (1999) 
18:141–50. doi:10.1097/00006676-199903000-00005 
30. Ogawa M. Acute pancreatitis and cytokines: “second attack” by sep-
tic complication leads to organ failure. Pancreas (1998) 16:312–5. 
doi:10.1097/00006676-199804000-00017 
31. Gerard C. Complement C5a in the sepsis syndrome – too much of a good 
thing? N Engl J Med (2003) 348:167–9. doi:10.1056/NEJMcibr022995 
32. Ward PA. The dark side of C5a in sepsis. Nat Rev Immunol (2004) 4:133–42. 
doi:10.1038/nri1269 
33. Czermak BJ, Sarma V, Pierson CL, Warner RL, Huber-Lang M, Bless NM, 
et al. Protective effects of C5a blockade in sepsis. Nat Med (1999) 5:788–92. 
doi:10.1038/10512 
34. Flierl MA, Schreiber H, Huber-Lang MS. The role of complement, C5a and 
its receptors in sepsis and multiorgan dysfunction syndrome. J Invest Surg 
(2006) 19:255–65. doi:10.1080/08941930600778263 
35. Hoehlig K, Maasch C, Shushakova N, Buchner K, Huber-Lang M, Purschke 
WG, et  al. A novel C5a-neutralizing mirror-image (l-)aptamer prevents 
organ failure and improves survival in experimental sepsis. Mol Ther (2013) 
21:2236–46. doi:10.1038/mt.2013.178 
36. Roxvall L, Bengtson A, Heideman M. Anaphylatoxin generation in acute 
pancreatitis. J Surg Res (1989) 47:138–43. doi:10.1016/0022-4804(89)90078-4 
37. He ZJ, Matikainen MP, Alho H, Harmoinen A, Ahola T, Nordback I. 
Extrapancreatic organ impairment in caerulein induced pancreatitis. Ann 
Chir Gynaecol (1999) 88:112–7. 
38. Halangk W, Lerch MM, Brandt-Nedelev B, Roth W, Ruthenbuerger 
M, Reinheckel T, et  al. Role of cathepsin B in intracellular trypsinogen 
manuscript, critical revision of the work, final approval, and 
agreement to any part of the work. MH-L contributed to the 
conception, design, and drafting of the manuscript, design of the 
figures, writing of the manuscript, final approval, and agreement 
to any part of the work.
FUNDiNG
This study was supported by grants from the German Research 
Foundation DFG assigned to the Collaborative Research Centre 
1149 “Trauma” (A01, Z02).
10
Bettac et al. Complement in Pancreatic Disease
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 15
activation and the onset of acute pancreatitis. J Clin Invest (2000) 106:773–81. 
doi:10.1172/JCI9411 
39. Seelig R, Ehemann V, Tschahargane C, Seelig HP. The serum complement 
system – a mediator of acute pancreatitis. Virchows Arch A Pathol Anat Histol 
(1975) 365:193–9. doi:10.1007/BF00434038 
40. Seelig R, Seelig HP. Complement-mediated acinar cell necroses in pancreati-
tis induced by basement membrane antibodies. Virchows Arch A Pathol Anat 
Histol (1976) 371:69–77. doi:10.1007/BF00433716 
41. Seelig R, Seelig HP, Rohnaeher R. Acute pancreatitis induced by intrapan-
creatic complement activation in the rat. Z Gastroenterol (1976) 14:654–67. 
42. Goldstein IM, Cala D, Radin A, Kaplan HB, Horn J, Ranson J. Evidence 
of complement catabolism in acute pancreatitis. Am J Med Sci (1978) 
275:257–64. doi:10.1097/00000441-197805000-00003 
43. Kelly RH, Rao KN, Harvey VS, Lombardi B. Acute hemorrhagic pancre-
atic necrosis in mice: lack of a pathogenetic role for complement. Acta 
Hepatogastroenterol (Stuttg) (1979) 26:302–9. 
44. Kelly RH, Rao KN, Harvey VS, Lombardi B. Acute hemorrhagic pancreatic 
necrosis in mice: alterations of serum complement. Digestion (1981) 22:1–7. 
doi:10.1159/000198588 
45. Roxvall L, Bengtson A, Sennerby L, Heideman M. Activation of the com-
plement cascade by trypsin. Biol Chem Hoppe Seyler (1991) 372:273–8. 
doi:10.1515/bchm3.1991.372.1.273 
46. Lasson A, Laurell AB, Ohlsson K. Correlation among complement activation, 
protease inhibitors, and clinical course in acute pancreatitis in man. Scand 
J Gastroenterol (1985) 20:335–45. doi:10.3109/00365528509091661 
47. Roxvall LI, Bengtson LA, Heideman JM. Anaphylatoxins and terminal com-
plement complexes in pancreatitis. Evidence of complement activation in 
plasma and ascites fluid of patients with acute pancreatitis. Arch Surg (1990) 
125:918–21. doi:10.1001/archsurg.1990.01410190116019 
48. Hartwig W, Klafs M, Kirschfink M, Hackert T, Schneider L, Gebhard MM, 
et al. Interaction of complement and leukocytes in severe acute pancreatitis: 
potential for therapeutic intervention. Am J Physiol Gastrointest Liver Physiol 
(2006) 291:G844–50. doi:10.1152/ajpgi.00016.2006 
49. Seelig R, Lankisch PG, Koop H, Winckler K, Kaboth U, Seelig HP. 
Complement system in sodium taurocholate pancreatitis in the rat. Res Exp 
Med (Berl) (1978) 174:57–65. doi:10.1007/BF01851939 
50. Antal L, Kavai M, Varhelyi I, Szegedi G. Abnormalities in humoral and 
cellular immune activity in pancreatitis. I. Study of the humoral immune 
system. Acta Med Acad Sci Hung (1978) 35:69–79. 
51. Gloor B, Stahel PF, Muller CA, Schmidt OI, Buchler MW, Uhl W. Predictive 
value of complement activation fragments C3a and sC5b-9 for development 
of severe disease in patients with acute pancreatitis. Scand J Gastroenterol 
(2003) 38:1078–82. doi:10.1080/00365520310005965 
52. Lasson A, Ohlsson K. Pancreatic pseudocysts: a biochemical evaluation of 
proteases and protease inhibitors in plasma. Scand J Gastroenterol (1987) 
22:355–61. doi:10.3109/00365528709078604 
53. Merriam LT, Webster C, Joehl RJ. Complement component C5 deficiency 
reduces edema formation in murine ligation-induced acute pancreatitis. 
J Surg Res (1997) 67:40–5. doi:10.1006/jsre.1996.4916 
54. Novovic S, Andersen AM, Ersboll AK, Jorgensen LN, Nielsen HJ, Jensenius 
JC, et  al. Mannan-binding lectin and mannan-binding lectin-associated 
serine protease 2 in acute pancreatitis. Pancreas (2011) 40:1097–102. 
doi:10.1097/MPA.0b013e31821b5a72 
55. Zhang H, Patel SA, Kandil E, Mueller CM, Lin YY, Zenilman ME. Pancreatic 
elastase is proven to be a mannose-binding protein – implications for the 
systemic response to pancreatitis. Surgery (2003) 133:678–88. doi:10.1067/
msy.2003.175 
56. Balldin G, Eddeland A, Ohlsson K. Studies on the role of the plasma pro-
tease inhibitors on in  vitro C3 activation and in acute pancreatitis. Scand 
J Gastroenterol (1981) 16:603–9. doi:10.3109/00365528109182018 
57. Horn JK, Ranson JH, Goldstein IM, Weissler J, Curatola D, Taylor R, et al. 
Evidence of complement catabolism in experimental acute pancreatitis. Am 
J Pathol (1980) 101:205–16. 
58. Lasson A, Ohlsson K. On the potential role of trypsin and trypsin 
inhibitors in acute pancreatitis. Adv Exp Med Biol (1984) 167:477–87. 
doi:10.1007/978-1-4615-9355-3_42 
59. Schmid S, Uhl W, Buchler MW. Protease-antiprotease interactions and the 
rationale for therapeutic protease inhibitors. Scand J Gastroenterol Suppl 
(1996) 219:47–50. doi:10.3109/00365529609105000 
60. Ohlsson K. Influence of the human pancreatic secretory trypsin inhibitor 
on trypsin-induced C3 and kininogen cleavage: an in  vitro study. Scand 
J Gastroenterol Suppl (1986) 126:18–20. doi:10.3109/00365528609091886 
61. Zhang C, Ge CL, Guo RX, He SG. Effect of IL-4 on altered expression of 
complement activation regulators in rat pancreatic cells during severe acute 
pancreatitis. World J Gastroenterol (2005) 11:6770–4. doi:10.3748/wjg.v11.
i43.6770 
62. Shrivastava P, Bhatia M. Essential role of monocytes and macrophages in the 
progression of acute pancreatitis. World J Gastroenterol (2010) 16:3995–4002. 
doi:10.3748/wjg.v16.i32.3995 
63. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J. The role of the 
anaphylatoxins in health and disease. Mol Immunol (2009) 46:2753–66. 
doi:10.1016/j.molimm.2009.04.027 
64. Solomkin JS, Cotta LA, Satoh PS, Hurst JM, Nelson RD. Complement 
activation and clearance in acute illness and injury: evidence for C5a as a 
cell-directed mediator of the adult respiratory distress syndrome in man. 
Surgery (1985) 97:668–78. 
65. Hartwig W, Jimenez RE, Fernandez-del CC, Kelliher A, Jones R, Warshaw AL. 
Expression of the adhesion molecules Mac-1 and L-selectin on neutrophils in 
acute pancreatitis is protease- and complement-dependent. Ann Surg (2001) 
233:371–8. doi:10.1097/00000658-200103000-00011 
66. Hatano N, Sugiyama M, Watanabe T, Atomi Y. Opsonin receptor expres-
sion on peritoneal exudative and circulatory neutrophils in murine acute 
pancreatitis. Pancreas (2001) 23:55–61. doi:10.1097/00006676-200107000- 
00008 
67. Sugiyama M, Hatano N, Watanabe T, Atomi Y. Acute necrotizing pancreatitis 
reduces opsonin receptor expression on peritoneal exudative neutrophils in 
mice. Hepatogastroenterology (2005) 52:1591–5. 
68. Kyriakides C, Jasleen J, Wang Y, Moore FD Jr, Ashley SW, Hechtman 
HB. Neutrophils, not complement, mediate the mortality of 
experimental hemorrhagic pancreatitis. Pancreas (2001) 22:40–6. 
doi:10.1097/00006676-200101000-00007 
69. Bhatia M, Saluja AK, Singh VP, Frossard JL, Lee HS, Bhagat L, et  al. 
Complement factor C5a exerts an anti-inflammatory effect in acute pan-
creatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol 
(2001) 280:G974–8. 
70. Huber-Lang MS, Younkin EM, Sarma JV, McGuire SR, Lu KT, Guo RF, 
et al. Complement-induced impairment of innate immunity during sepsis. 
J Immunol (2002) 169:3223–31. doi:10.4049/jimmunol.169.6.3223 
71. Muraki T, Hamano H, Ochi Y, Komatsu K, Komiyama Y, Arakura N, et al. 
Autoimmune pancreatitis and complement activation system. Pancreas 
(2006) 32:16–21. doi:10.1097/01.mpa.0000188308.75043.e4 
72. Okazaki K, Uchida K, Fukui T, Takaoka M, Nishio A. Autoimmune pan-
creatitis – a new evolving pancreatic disease? Langenbecks Arch Surg (2010) 
395:989–1000. doi:10.1007/s00423-010-0714-2 
73. Detlefsen S, Brasen JH, Zamboni G, Capelli P, Kloppel G. Deposition of com-
plement C3c, immunoglobulin (Ig)G4 and IgG at the basement membrane 
of pancreatic ducts and acini in autoimmune pancreatitis. Histopathology 
(2010) 57:825–35. doi:10.1111/j.1365-2559.2010.03717.x 
74. Sendler M, Beyer G, Mahajan UM, Kauschke V, Maertin S, Schurmann C, et al. 
Complement component 5 mediates development of fibrosis, via activation 
of stellate cells, in 2 mouse models of chronic pancreatitis. Gastroenterology 
(2015) 149:765–76. doi:10.1053/j.gastro.2015.05.012 
75. Ravindranath NM, Shuler C. Cell-surface density of complement restriction 
factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other 
solid tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2007) 
103:231–9. doi:10.1016/j.tripleo.2006.05.028 
76. Schmitt CA, Schwaeble W, Wittig BM, Meyer zum Buschenfelde KH, 
Dippold WG. Expression and regulation by interferon-gamma of the mem-
brane-bound complement regulators CD46 (MCP), CD55 (DAF) and CD59 
in gastrointestinal tumours. Eur J Cancer (1999) 35:117–24. doi:10.1016/
S0959-8049(98)00290-1 
77. Juhl H, Helmig F, Baltzer K, Kalthoff H, Henne-Bruns D, Kremer B. Frequent 
expression of complement resistance factors CD46, CD55, and CD59 on 
gastrointestinal cancer cells limits the therapeutic potential of monoclonal 
antibody 17-1A. J Surg Oncol (1997) 64:222–30. 
78. Roeise O, Sivertsen S, Ruud TE, Bouma BN, Stadaas JO, Aasen AO. Studies 
on components of the contact phase system in patients with advanced 
gastrointestinal cancer. Cancer (1990) 65:1355–9. 
11
Bettac et al. Complement in Pancreatic Disease
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 8 | Article 15
79. Schiarea S, Solinas G, Allavena P, Scigliuolo GM, Bagnati R, Fanelli R, 
et  al. Secretome analysis of multiple pancreatic cancer cell lines reveals 
perturbations of key functional networks. J Proteome Res (2010) 9:4376–92. 
doi:10.1021/pr1001109 
80. Andoh A, Shimada M, Takaya H, Hata K, Fujiyama Y, Bamba T. Transforming 
growth factor-beta1 acts as a potent inhibitor of complement C3 biosyn-
thesis in human pancreatic cancer cell lines. Pancreas (2000) 20:138–45. 
doi:10.1097/00006676-200003000-00005 
81. Neuzillet C, de Gramont A, Tijeras-Raballand A, de Mestier L, Cros J, 
Faivre S, et al. Perspectives of TGF-β inhibition in pancreatic and hepatocel-
lular carcinomas. Oncotarget (2014) 5:78–94. doi:10.18632/oncotarget.1569
82. Arshad A, Chung W, Isherwood J, Steward W, Metcalfe M, Dennison A. 
Restoration of mannose-binding lectin complement activity is associated 
with improved outcome in patients with advanced pancreatic cancer treated 
with gemcitabine and intravenous omega-3 fish oil. JPEN J Parenter Enteral 
Nutr (2014) 38:214–9. doi:10.1177/0148607113476304 
83. Chen J, Wu W, Chen L, Zhou H, Yang R, Hu L, et al. Profiling the potential 
tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and 
MALDI-TOF-MS: up-regulation of complement C3 and alpha-2-HS-glyco-
protein. Pancreatology (2013) 13:290–7. doi:10.1016/j.pan.2013.03.010 
84. Hanas JS, Hocker JR, Cheung JY, Larabee JL, Lerner MR, Lightfoot SA, et al. 
Biomarker identification in human pancreatic cancer sera. Pancreas (2008) 
36:61–9. doi:10.1097/mpa.0b013e3180d0a738 
85. Padoan A, Seraglia R, Basso D, Fogar P, Sperti C, Moz S, et al. Usefulness 
of MALDI-TOF/MS identification of low-MW fragments in sera for the 
differential diagnosis of pancreatic cancer. Pancreas (2013) 42:622–32. 
doi:10.1097/MPA.0b013e318273096c 
86. Starzynska T, Dabkowski K, Blogowski W, Zuba-Surma E, Budkowska M, 
Salata D, et al. An intensified systemic trafficking of bone marrow-derived 
stem/progenitor cells in patients with pancreatic cancer. J Cell Mol Med 
(2013) 17:792–9. doi:10.1111/jcmm.12065 
87. Marten A, Buchler MW, Werft W, Wente MN, Kirschfink M, Schmidt 
J. Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior 
to CA19.9 and radiology. J Immunother (2010) 33:219–24. doi:10.1097/
CJI.0b013e3181bed29f 
88. Lee MJ, Na K, Jeong SK, Lim JS, Kim SA, Lee MJ, et  al. Identification of 
human complement factor B as a novel biomarker candidate for pancreatic 
ductal adenocarcinoma. J Proteome Res (2014) 13:4878–88. doi:10.1021/
pr5002719 
89. Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, et al. 
iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of 
obstructive jaundice on their performance. Br J Cancer (2013) 108:1846–53. 
doi:10.1038/bjc.2013.150 
90. Chen J, Wu W, Zhen C, Zhou H, Yang R, Chen L, et al. Expression and clinical 
significance of complement C3, complement C4b1 and apolipoprotein E in 
pancreatic cancer. Oncol Lett (2013) 6:43–8. doi:10.3892/ol.2013.1326
91. Contractor T, Kobayashi S, da Silva E, Clausen R, Chan C, Vosburgh E, et al. 
Sexual dimorphism of liver metastasis by murine pancreatic neuroendocrine 
tumors is affected by expression of complement C5. Oncotarget (2016) 
7(21):30585–96. doi:10.18632/oncotarget.8874 
92. Yamaguchi H, Weidenbach H, Luhrs H, Lerch MM, Dickneite G, Adler 
G. Combined treatment with C1 esterase inhibitor and antithrombin III 
improves survival in severe acute experimental pancreatitis. Gut (1997) 
40:531–5. doi:10.1136/gut.40.4.531 
93. Schneider DT, Nurnberger W, Stannigel H, Bonig H, Gobel U. Adjuvant treat-
ment of severe acute pancreatitis with C1 esterase inhibitor concentrate after 
haematopoietic stem cell transplantation. Gut (1999) 45:733–6. doi:10.1136/
gut.45.5.733 
94. Cicardi M, Testoni P, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, et al. 
Antiproteasic activity of C1 inhibitor. Therapeutic perspectives. Ann Ital Med 
Int (1994) 9:180–2. 
95. Weiser MR, Gibbs SA, Moore FD Jr, Hechtman HB. Complement inhibition 
by soluble complement receptor type 1 fails to moderate cerulein-induced 
pancreatitis in the rat. Int J Pancreatol (1996) 19:129–34. 
96. Acioli JM, Isobe M, Kawasaki S. Early complement system activation and 
neutrophil priming in acute pancreatitis: participation of trypsin. Surgery 
(1997) 122:909–17. doi:10.1016/S0039-6060(97)90332-9 
97. Emori Y, Mizushima T, Matsumura N, Ochi K, Tanioka H, Shirahige 
A, et  al. Camostat, an oral trypsin inhibitor, reduces pancreatic 
fibrosis induced by repeated administration of a superoxide dis-
mutase inhibitor in rats. J Gastroenterol Hepatol (2005) 20:895–9. 
doi:10.1111/j.1440-1746.2005.03826.x 
98. Seta T, Noguchi Y, Shikata S, Nakayama T. Treatment of acute pancreatitis 
with protease inhibitors administered through intravenous infusion: an 
updated systematic review and meta-analysis. BMC Gastroenterol (2014) 
14:102. doi:10.1186/1471-230X-14-102 
99. Markiewski MM, Lambris JD. Is complement good or bad for cancer patients? 
A new perspective on an old dilemma. Trends Immunol (2009) 30:286–92. 
doi:10.1016/j.it.2009.04.002 
100. Markiewski MM, Deangelis RA, Benencia F, Ricklin-Lichtsteiner SK, 
Koutoulaki A, Gerard C, et  al. Modulation of the antitumor immune 
response by complement. Nat Immunol (2008) 9:1225–35. doi:10.1038/ 
ni.1655 
101. Markiewski MM, Lambris JD. Unwelcome complement. Cancer Res (2009) 
69:6367–70. doi:10.1158/0008-5472.CAN-09-1918 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2017 Bettac, Denk, Seufferlein and Huber-Lang. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
